PMID- 30816354
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220408
IS  - 2587-0831 (Print)
IS  - 2587-0831 (Electronic)
VI  - 15
IP  - 1
DP  - 2019 Jan
TI  - HER-2/Neu and Hormone Receptor Analysis in Breast Carcinomas and Their 
      Association with Clinicopathologic Parameters.
PG  - 43-50
LID - 10.5152/ejbh.2018.4118 [doi]
AB  - OBJECTIVE: Invasive breast carcinomas of no special type (IC-NST) are the 
      heterogeneous tumours showing distinct prognostic features even in patients with 
      similar clinicopathological characteristics. To date, many clinicopathological 
      data have been analyzed to make a guess about prognosis and to determine 
      treatment modality. In this study, HER-2/neu status was analyzed by using both 
      immunohistochemical (IHC) and fluorescence in situ hybridization (FISH) methods, 
      and its correlations with hormone receptor status and clinicopathological 
      parameters were investigated. MATERIALS AND METHODS: The study was included 112 
      female patients with diagnosis of IC-NST. FISH for HER-2/neu was applied in only 
      primary tumour tissues, while IHC analyses for HER-2/neu, estrogen (ER) and 
      progesterone receptors (PR) were applied on both primary and metastatic lymph 
      node foci. The results were compared with appropriate statistical methods. 
      RESULTS: Our rates of HER-2/neu overexpression and gene amplification in the 
      overall study group were 22.3 and 25%, respectively. In the metastatic group, 
      these rates were higher than those of the overall study group (34% and 40%, 
      respectively). Gene amplification rate of the axilla positive group was 40%, 
      while this rate in non-metastatic group was 6.7% (p=0.015). Overexpression and 
      amplification results were compliant (chi(2)=77,591, p<0.001). The concordance 
      rates in HER-2/neu negative and overexpression groups were 95.3% and 88%, 
      respectively. Our false negativity rate was 4.7%. While 36% of score 3+ cases 
      were ER positive, 67.1% of HER-2/neu negative cases showed ER positivity 
      (p=0.01). The increase of gene amplification rate in ER negative cases over 50 
      years age was more than two times and statistically significant (p=0.014). 
      CONCLUSION: The concordance rates between the results of IHC and FISH in the 
      HER-2 negative and the overexpression categories were compatible with the 
      literature and lower than the literature, respectively. In the case of ER 
      negativity, the patient's age over 50 years was associated with a higher rate of 
      gene amplification.
FAU - Koseoglu, Resit Dogan
AU  - Koseoglu RD
AUID- ORCID: 0000-0001-7389-6811
AD  - Department of Pathology, Gaziosmanpasa University School of Medicine, Tokat, 
      Turkey.
FAU - Markoc, Fatma
AU  - Markoc F
AUID- ORCID: 0000-0003-4219-3333
AD  - Department of Pathology, Gaziosmanpasa University School of Medicine, Tokat, 
      Turkey.
FAU - Muslehiddinoglu, Ahmet
AU  - Muslehiddinoglu A
AUID- ORCID: 0000-0003-0769-5952
AD  - Department of Pathology, Tokat State Hospital, Tokat, Turkey.
FAU - Ileri, Ayse Burcu
AU  - Ileri AB
AUID- ORCID: 0000-0002-1327-3871
AD  - Department of Pathology, Gaziosmanpasa University School of Medicine, Tokat, 
      Turkey.
FAU - Deresoy, Faik Alev
AU  - Deresoy FA
AUID- ORCID: 0000-0002-2243-9394
AD  - Department of Pathology, Gaziosmanpasa University School of Medicine, Tokat, 
      Turkey.
FAU - Etikan, Ilker
AU  - Etikan I
AUID- ORCID: 0000-0001-9171-8269
AD  - Department of Biostatistics, Gaziosmanpasa University School of Medicine, Tokat, 
      Turkey.
LA  - eng
PT  - Journal Article
DEP - 20181024
PL  - Turkey
TA  - Eur J Breast Health
JT  - European journal of breast health
JID - 101709357
PMC - PMC6385718
OTO - NOTNLM
OT  - Breast
OT  - FISH
OT  - HER-2/neu
OT  - hormone receptors
OT  - immunohistochemistry
OT  - invasive carcinoma
COIS- Conflict of Interest: The authors have no conflicts of interest to declare.
EDAT- 2019/03/01 06:00
MHDA- 2019/03/01 06:01
PMCR- 2018/10/24
CRDT- 2019/03/01 06:00
PHST- 2018/03/29 00:00 [received]
PHST- 2018/07/15 00:00 [accepted]
PHST- 2019/03/01 06:00 [entrez]
PHST- 2019/03/01 06:00 [pubmed]
PHST- 2019/03/01 06:01 [medline]
PHST- 2018/10/24 00:00 [pmc-release]
AID - ejbh-15-1-43 [pii]
AID - 10.5152/ejbh.2018.4118 [doi]
PST - epublish
SO  - Eur J Breast Health. 2018 Oct 24;15(1):43-50. doi: 10.5152/ejbh.2018.4118. 
      eCollection 2019 Jan.